Ghent University Academic Bibliography

Advanced

Rhenium-188 based radiopharmaceuticals for treatment of liver tumours

Bieke Lambert UGent, Klaus Bacher UGent and Luc Defreyne UGent (2009) QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 53(3). p.305-310
abstract
Rhenium-188 (Re-188) is a high energy beta-emitter with a physical half life of 17 hours. Various 188Re based radiopharmaceuticals were developed to treat liver malignancies. The vast majority of studies focus on patients suffering from hepatocellular carcinoma (HCC). Most radiopharmaceuticals are based on Lipiodol as a vehicle for the rhenium-188. The radiopharmaceutical that was tested clinically hi detail is the Re-188-HDD/Lipiodol, developed by the Seoul University. Clinical data derived from several phase I and 11 studies using Re-188-HDD/Lipiodol suggest an excellent tolerance in patients with Child-Pugh A cirrhosis. A shortcoming in some trials was the occasional low labelling efficiency of Re-188-HDD/Lipiodol. Some newer 188Re based radiopharmaceuticals claim to have consistent high labelling efficiencies, however clinical data for these compounds are scarce or lacking at this moment. Hopefully, phase I clinical data will become available for promising radiopharmaceuticals such as Re-188-SSS-Lipiodol, developed by the group of Rennes, in the upcoming years. In Dresden a very different approach is used. They labelled human serum albumin microspheres with high activities of Re-188 in a small group of patients with liver metastasis and a few HCC patients, treatment proved safe. in the present clinical field, Re-188-based radiopharmaceuticals will have to proof firmly their strength and reliability in large patient groups if they want to compete with the commercially available yttrium-90 microspheres
Please use this url to cite or link to this publication:
author
organization
year
type
journalArticle (review)
publication status
published
subject
journal title
QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
Q. J. Nucl. Med. Mol. Imag.
volume
53
issue
3
pages
305 - 310
Web of Science type
Review
Web of Science id
000268849500005
JCR category
RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
JCR impact factor
2.877 (2009)
JCR rank
23/104 (2009)
JCR quartile
1 (2009)
ISSN
1824-4661
language
English
UGent publication?
yes
classification
A1
id
809385
handle
http://hdl.handle.net/1854/LU-809385
date created
2009-12-14 09:54:28
date last changed
2009-12-16 10:20:31
@article{809385,
  abstract     = {Rhenium-188 (Re-188) is a high energy beta-emitter with a physical half life of 17 hours. Various 188Re based radiopharmaceuticals were developed to treat liver malignancies. The vast majority of studies focus on patients suffering from hepatocellular carcinoma (HCC). Most radiopharmaceuticals are based on Lipiodol as a vehicle for the rhenium-188. The radiopharmaceutical that was tested clinically hi detail is the Re-188-HDD/Lipiodol, developed by the Seoul University. Clinical data derived from several phase I and 11 studies using Re-188-HDD/Lipiodol suggest an excellent tolerance in patients with Child-Pugh A cirrhosis. A shortcoming in some trials was the occasional low labelling efficiency of Re-188-HDD/Lipiodol. Some newer 188Re based radiopharmaceuticals claim to have consistent high labelling efficiencies, however clinical data for these compounds are scarce or lacking at this moment. Hopefully, phase I clinical data will become available for promising radiopharmaceuticals such as Re-188-SSS-Lipiodol, developed by the group of Rennes, in the upcoming years. In Dresden a very different approach is used. They labelled human serum albumin microspheres with high activities of Re-188 in a small group of patients with liver metastasis and a few HCC patients, treatment proved safe. in the present clinical field, Re-188-based radiopharmaceuticals will have to proof firmly their strength and reliability in large patient groups if they want to compete with the commercially available yttrium-90 microspheres},
  author       = {Lambert, Bieke and Bacher, Klaus and Defreyne, Luc},
  issn         = {1824-4661},
  journal      = {QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING},
  language     = {eng},
  number       = {3},
  pages        = {305--310},
  title        = {Rhenium-188 based radiopharmaceuticals for treatment of liver tumours},
  volume       = {53},
  year         = {2009},
}

Chicago
Lambert, Bieke, Klaus Bacher, and Luc Defreyne. 2009. “Rhenium-188 Based Radiopharmaceuticals for Treatment of Liver Tumours.” Quarterly Journal of Nuclear Medicine and Molecular Imaging 53 (3): 305–310.
APA
Lambert, Bieke, Bacher, K., & Defreyne, L. (2009). Rhenium-188 based radiopharmaceuticals for treatment of liver tumours. QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 53(3), 305–310.
Vancouver
1.
Lambert B, Bacher K, Defreyne L. Rhenium-188 based radiopharmaceuticals for treatment of liver tumours. QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2009;53(3):305–10.
MLA
Lambert, Bieke, Klaus Bacher, and Luc Defreyne. “Rhenium-188 Based Radiopharmaceuticals for Treatment of Liver Tumours.” QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING 53.3 (2009): 305–310. Print.